Grafa News and Videos — Page 864

DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.

Nebius Group (NASDAQ:NBIS) reported a first-quarter profit of $621.2 million, or $2.11 per share.

CTW (NASDAQ:CTW) announced Wednesday that revenue for the six months ending January 31, 2026, reached $40.9 million, a 1% decline from the $41.2 million reported in the prior-year period.

Costamare Bulkers (NYSE:CMDB) reported first-quarter net income of $9.9 million, or $0.41 per share.

Valens Semiconductor (NYSE:VLN) posted first-quarter revenue of $16.9 million, edging past its guidance range of $16.3 million to $16.7 million.

Pfizer (NYSE:PFE) announced Wednesday that European regulators have cleared Hympavzi for adolescents and adults with hemophilia A or B with inhibitors, marking a significant expansion for the non-factor therapy in the 27 EU member states, Iceland, Liechtenstein, and Norway.

Aprea Therapeutics (NASDAQ:APRE) announced Wednesday that it ended the first quarter with $46.5 million in cash and cash equivalents, a sharp increase from the end of 2025.

Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.

BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.

Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company developing treatments for metabolic and liver diseases, reported its first-quarter 2026 financial results and provided a business update.